Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epicardial Injection of HiCM-188 in CABG for Severe Chronic Ischemic Heart Failure
ChiCTR2600117368Phase 2Completed
- Sponsor
- Tianjin TEDA International Cardiovascular Hospital
- Start
- Jan 2026
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of HiCM-188 in heart failure (HF) (3 arms), sponsored by Tianjin TEDA International Cardiovascular Hospital. Primary endpoint: Incidence of major serious adverse events. Started Jan 2026; status: completed.
02
Drugs
HiCM-188
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2600117368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117368.